SCHEMBL7130577

SCHEMBL7130577

Fc1cc(Br)c(OCCCCN2CCN(C3=COC(C4=CC=CCC4)=CO3)CC2)c(Br)c1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
HRH3 Q9Y5N1 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
HTR1A P08908 2/20 0.31
HTR2A P28223 2/20 0.31
USP2 O75604 1/20 0.30
HPGD P15428 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
LMNA P02545 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
DRD2 P14416 1/20 0.30
DRD1 P21728 1/20 0.30
DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7123102 0.98 HRH3 (0.35) ALDH1A1HRH3KDM4EMEN1KMT2A
SCHEMBL7127897 0.94 HRH3 (0.32) ALDH1A1HRH3HTR1AHTR2ASIGMAR1
SCHEMBL7121636 0.91
SCHEMBL7126591 0.91 ALDH1A1 (0.34) ALDH1A1SLC6A2SLC6A4HTR1AHTR2A
SCHEMBL7122251 0.91 ALDH1A1 (0.37) ALDH1A1HRH3KDM4EMEN1KMT2A
SCHEMBL7124375 0.89 HTR1A (0.33) ALDH1A1HTR1AHTR2ASIGMAR1DRD2
SCHEMBL7123069 0.89 HTR1A (0.33) ALDH1A1KMT2ASLC6A2SLC6A4HTR1A
SCHEMBL7118092 0.89 HTR1A (0.33) SLC6A2SLC6A4HTR1AHTR2ASIGMAR1
SCHEMBL7123074 0.89 LMNA (0.38) ALDH1A1KDM4EMEN1KMT2ASLC6A2
SCHEMBL7122257 0.87 LMNA (0.32) ALDH1A1KMT2ASLC6A2SLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 ALDH1A1 2108/4885HRH3 787/4885KDM4E 2331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.